Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer - Report - MDSpire

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • By

  • Meghna S. Trivedi

  • Joseph M. Unger

  • N. Lynn Henry

  • Amy K. Darke

  • Daniel L. Hertz

  • Thomas H. Brannagan

  • Stephanie J. Reyes

  • Bryan P. Schneider

  • William J. Irvin

  • Amanda R. Hathaway

  • Amy C. Vander Woude

  • Vinay K. Gudena

  • Paula Cabrera-Galeana

  • Mary Orsted

  • Michael LeBlanc

  • Michael J. Fisch

  • Dawn L. Hershman

  • April 10, 2026

  • 0 min

Share

Clinical Report: Predictive Model for Assessing the Risk of TIPN

Overview

Revise to specify that TIPN occurs in up to 70% of patients undergoing taxane therapy, as per the source.

Background

Taxanes are commonly used in treating various cancers but can lead to TIPN, significantly impacting patient quality of life and treatment outcomes. Effective management of TIPN is limited, often relying on dose modifications that may adversely affect long-term survival. Understanding risk factors for TIPN is crucial for optimizing treatment strategies and improving patient care.

Data Highlights

Risk FactorsImpact on TIPN
AgeIncreased risk
Body Mass IndexIncreased risk
DiabetesIncreased risk
Cumulative Taxane DoseIncreased risk
Type of TaxaneVaried risk

Key Findings

  • TIPN affects up to 70% of patients receiving taxane therapy.
  • Patient-related factors include age, BMI, diabetes, and genetic predispositions.
  • Taxane dose modifications are the primary management strategy for TIPN.
  • Prior studies have shown inconsistent results regarding risk factors due to methodological differences.
  • The SWOG S1714 study aims to validate a TIPN risk prediction model through a prospective cohort design.

Clinical Implications

Clinicians should be aware of the significant risk factors for TIPN when planning taxane-based chemotherapy. Early identification of at-risk patients may facilitate proactive management strategies, potentially improving treatment adherence and patient outcomes.

Conclusion

The development of a predictive model for TIPN represents a significant step towards personalized cancer treatment. By identifying patients at higher risk, clinicians can better manage taxane therapy and mitigate the adverse effects of TIPN.

References

  1. The ASCO Post, 2012 -- Neuropathy Not Predictive of Outcomes with Adjuvant Taxane Therapy in Breast Cancer
  2. The ASCO Post, 2023 -- Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
  3. The ASCO Post, 2012 -- Taxane-induced Neuropathy Does Not Correlate with Improved Outcomes in Operable Breast Cancer
  4. The ASCO Post, 2012 -- Two Single Nucleotide Polymorphisms Associated with Risk for Paclitaxel-related Peripheral Neuropathy
  5. Regional Anesthesia & Pain Medicine, 2025 -- Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy
  6. Accurate Clinic, 2020 -- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
  7. PMC, 2023 -- Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer
  8. Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24 | Regional Anesthesia & Pain Medicine
  9. Prevention and Management of
  10. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer - PMC

Original Source(s)

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • by Meghna S. Trivedi, Joseph M. Unger, N. Lynn Henry, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan, Stephanie J. Reyes, Bryan P. Schneider, William J. Irvin, Amanda R. Hathaway, Amy C. Vander Woude, Vinay K. Gudena, Paula Cabrera-Galeana, Mary Orsted, Michael LeBlanc, Michael J. Fisch, Dawn L. Hershman

  • April 10, 2026

Related Content

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

  • by

  • May 25, 2026

  • 9 min